Skip to search formSkip to main contentSkip to account menu

EPO906

Known as: EPO-906A 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

epothilone B

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
Concurrent radiochemotherapy for medulloblastoma includes the microtubule disrupting agent vincristine; however, vincristine… 
Review
2008
Review
2008
Ixabepilone in Metastatic Breast Cancer: Complement or Alternative to Taxanes?
Targeting the microtubule is a successful strategy in the treatment of solid tumors. There is an ongoing effort to develop newer… 
Highly Cited
2005
Highly Cited
2005
Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo
Microtubule agents appear promising for the treatment of prostate cancer. Patupilone (epothilone B), a highly potent non‐taxane… 
2005
2005
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma
PurposeThe microtubule-stabilizing agent patupilone (epothilone B, EPO906) and the tyrosine kinase inhibitor imatinib (STI571… 
2005
2005
The epothilone dilemma.
Because of their potent antitumor activity, drugs targeting microtubules are among the most commonly prescribed anticancer agents… 
2005
2005
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.
In this study, we investigated the in vitro and in vivo efficacy of patupilone (epothilone B, EPO906), a novel nontaxane… 
2005
2005
Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells In vitro and In vivo
Interference with microtubule function is a promising antitumoral concept. Paclitaxel is a clinically validated tubulin-targeting… 
2004
2004
A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC)
4563 Background: Single-agent taxanes have demonstrated clinical activity in HPRC; however, the median duration of response is… 
2004
2004
A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC).
4563 Background: Single-agent taxanes have demonstrated clinical activity in HPRC; however, the median duration of response is… 
2004
2004
Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer.
4623 Background: Estramustine in combination with taxanes has demonstrated synergistic antitumor activity in patients (pts) with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)